Excelsior Biopharma (6496) — Free Cash Flow Generation Index
Excelsior Biopharma (6496) has a Free Cash Flow Generation Index of -2.80x as of June 2025. Free cash flow of NT$-10.64 Million represents -3% of operating cash flow (NT$3.80 Million). See working capital to net assets of Excelsior Biopharma to evaluate short-term liquidity relative to the company's equity base.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Excelsior Biopharma Free Cash Flow Generation Index (2017–2022)
Historical FCF Generation Index trend for Excelsior Biopharma across 5 annual periods. Explore 6496 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Free Cash Flow Generation for Excelsior Biopharma (2017–2022)
Year-by-year Free Cash Flow Generation Index for Excelsior Biopharma. For the full company profile including market capitalisation, see Excelsior Biopharma market capitalisation.
| Year | FCG Index | Free Cash Flow (TWD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2022 | -0.42x | NT$-2.30 Million | NT$5.49 Million | NT$7.78 Million | ▼ -144.1% |
| 2021 | 0.95x | NT$52.95 Million | NT$55.82 Million | NT$2.88 Million | ▼ -3.0% |
| 2020 | 0.98x | NT$509.20 Million | NT$520.81 Million | NT$11.62 Million | ▲ +5.7% |
| 2018 | 0.92x | NT$117.38 Million | NT$126.92 Million | NT$9.54 Million | ▼ -2.4% |
| 2017 | 0.95x | NT$331.23 Million | NT$349.47 Million | NT$18.10 Million | — |